Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

ASH 2021

The 63rd ASH Annual Meeting and Exposition

11–14 December 2021 | Atlanta, GA

Breaking Updates in Hematological-Oncology

View all videos

VJHemOnc @VJHemOnc ·

17h 2010411562423509136

In a video interview from #ASH25, @VijayaRBhatt1 of @unmc shares the results of a Phase I trial evaluating the novel first-in-class agent ONC201 (dordaviprone) as post-transplant maintenance therapy in AML & MDS.

Find out more by clicking here:
👉

#AMLsm

Phase I trial of ONC201 as post-transplant maintenance for AML and MDS

Vijaya Bhatt, MBBS, University of Nebraska Medical Center, Omaha, NE, discusses the results of a Phase I trial (NC...

ow.ly

Reply on Twitter 2010411562423509136 Retweet on Twitter 2010411562423509136 0 Like on Twitter 2010411562423509136 2 View Tweet 2010411562423509136

VJHemOnc @VJHemOnc ·

11 Jan 2010275551328526721

At #ASH25, we spoke with the lovely @AbdulhaqHaifaa of @UCSF, who discussed a subgroup analysis from the STARGLO trial evaluating the efficacy of glofitamab plus GemOx versus R-GemOx in transplant-ineligible patients with R/R #DLBCL.

Watch now:
🎥

#LYMsm

Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO

Haifaa Abdulhaq, MD, University of California San Francisco, San Francisco, CA, discusses a subgroup analysis from the...

ow.ly

Reply on Twitter 2010275551328526721 Retweet on Twitter 2010275551328526721 0 Like on Twitter 2010275551328526721 2 View Tweet 2010275551328526721

VJHemOnc @VJHemOnc ·

10 Jan 2010049111274189147

It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.

Watch here: 👉

#MMSM

Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis

In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...

ow.ly

Reply on Twitter 2010049111274189147 Retweet on Twitter 2010049111274189147 1 Like on Twitter 2010049111274189147 4 View Tweet 2010049111274189147

VJHemOnc @VJHemOnc ·

10 Jan 2009905608930017597

🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:

👉 👈

#ASH25 #Hematology #CTSM

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial

Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...

ow.ly

Reply on Twitter 2009905608930017597 Retweet on Twitter 2009905608930017597 0 Like on Twitter 2009905608930017597 1 View Tweet 2009905608930017597

VJHemOnc @VJHemOnc ·

9 Jan 2009686860134572254

Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸

Click here: 👉

#MDSsm #CTSM #TrialUpdate #HemOnc

Updated results from a Phase II trial of elritercept in LR-MDS

Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...

ow.ly